Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147071 | 0.81 | FFAR1 (0.65) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL11442961 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL19604046 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTHSD17B10PKM | |
| Hydrochloric Acid SCHEMBL1376065 | 0.79 | FFAR1 (0.63) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL7421131 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL13113137 | 0.79 | PKM (0.51) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL3735703 | 0.79 | SMN1; SMN2 (0.60) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL1170309 | 0.78 | FFAR1 (0.68) | ALDH1A1LMNAHTTHSD17B10FFAR1 | |
| Hydrochloric Acid SCHEMBL11299977 | 0.78 | ALDH1A1 (0.47) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL10971632 | 0.77 | CA2 (0.47) | ALDH1A1HSD17B10PKMFFAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525057-B1 | ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMA (US) | 2000-06-14 | — | — | EP | claimed |
| EP-0379048-B1 | Beta-lactamase assays employing chromogenic precipitating substrates | ABBOTT LAB (US) | 1995-09-13 | — | — | EP | claimed |
| US-4978613-A | Beta-lactamase assay employing chromogenic precipitating substrates | ABBOTT LABORATORIES (US) | 1990-12-18 | — | — | US | claimed |
| EP-0379048-A2 | Beta-lactamase assays employing chromogenic precipitating substrates | ABBOTT LABORATORIES (US) | 1990-07-25 | — | — | EP | claimed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| US-4068073-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-4066761-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
| US-4059591-A | Ureidoalkyl substituted tetrazole thiol intermediates for preparing cephalosporins | SMITHKLINE CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-4057631-A | CEPHALOSPORINS, BACTERICIDE | SMITHKLINE CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4048311-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4041162-A | ANTIBIOTICS, BACTERICIDES | SMITHKLINE CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
| US-4034092-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
| US-4025626-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | ALDH1A1 1605/4885LMNA 2899/4885HTT 4361/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | ALDH1A1 876/4885LMNA 2190/4885HTT 4880/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | ALDH1A1 1605/4885LMNA 2899/4885HTT 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.